Genmab — Februar 2024
-
Haha - det svar er der ikke meget KYSO over! Tak for indsatsen w
-
-
Godmorgen
-
Godmorgen
@w, der er jo stille periode nu 14 dage før regnskabet så begrænset hvad svar man kan forvente. Men enig i Biotech er high risk i.f.t at investere i ETFer, index m.m. Men hvis alt går godt kan Genmab da sikkert slå SP500 index på den lange bane. Det har Genmab jo faktisk gjort hvis vi ser bort fra de sidste 2 år hvor den tabte voldgift og de høje renter vel er skyld i tab på ca. 1000 kurs point. -
The Average Profit Margin of Pharmaceuticals | Bizfluent
The pharmaceutical industry has some of the highest profit margins in the world, up to 45 percent for some of the largest companies in big pharma.
Bizfluent (bizfluent.com)
-
Epcoritamab on the EMA PRAC agenda, Scope: Extension of indication to include treatment of adult patients with relapsed or
refractory (R/R) follicular lymphoma (FL) after two or more lines https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-5-8-february-2024_en.pdf
= ?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind